The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas.
K. A. Robertson
No relevant relationships to disclose
D. C. Bowers
No relevant relationships to disclose
F. Yang
No relevant relationships to disclose
T. Vik
No relevant relationships to disclose
C. Ho
No relevant relationships to disclose
J. Croop
No relevant relationships to disclose
L. E. Walsh
No relevant relationships to disclose
C. Hingtgen
No relevant relationships to disclose
K. R. Pradhan
No relevant relationships to disclose
G. Hutchins
No relevant relationships to disclose
J. W. Fletcher
No relevant relationships to disclose
M. Cohen
No relevant relationships to disclose
M. Edwards-Brown
No relevant relationships to disclose
J. B. Travers
No relevant relationships to disclose
M. Yu
No relevant relationships to disclose
G. Nalepa
No relevant relationships to disclose
S. Denne
No relevant relationships to disclose
D. Ingram
No relevant relationships to disclose
W. Clapp
No relevant relationships to disclose